Anti-Aβ/Anti-TfR1: Trontinemab (RO7126209), a bispecific antibody targeting both Aβ and TfR1, is currently in Phase II development (NCT04639050, Brainshuttle AD trial) [139]. Here, TFRC is linked to Alzheimer disease.